Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Antiviral Res. 2019 Apr 7;167:25–34. doi: 10.1016/j.antiviral.2019.04.004

Table 3.

In vitro anti-WEEV (strain California) and anti-EEEV (strain FL93–939) activity of BDGR-4

WEEV
EC501 (nM)
WEEV
log titer
reduction2
EEEV
EC50 (nM)
EEEV
log titer
reduction
BDGR-4 102.3 ± 37.8 > 6.24* 149.5 ± 24 ND
1

cytopathic effect (CPE) assay in VERO76 cells;

2

done at 18 h post infection using 5 μM compound concentration in VERO76 cells. ;

*

No progeny virus plaques were detected. ND = not determined.